ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0181

Serum Trace Metal Changes Could Potentially Indicate Kidney Damage in Rats with Cisplatin-Induced Kidney Injury

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Hotta, Yuji, Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Tomita, Natsumi, Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Yamamoto, Yuko, Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Naiki-Ito, Aya, Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Sanagawa, Akimasa, Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
  • Kondo, Masahiro, Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan
  • Kataoka, Tomoya, Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Takahashi, Satoru, Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
  • Kimura, Kazunori, Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
Background

Cisplatin (CDDP), a widely used anticancer drug, is known to exhibit nephrotoxic adverse effects. Nephrotoxicity is a dose-limiting toxicity. Therefore, the early detection of cisplatin-induced nephrotoxicity is crucial. Certain trace metals reportedly change with kidney injury, although their relationship with CDDP-induced kidney injury remains unclear. Therefore, in this study, we investigated the trace metal changes after cisplatin treatment in rats.

Methods

Eight-week-old male Wistar-ST rats were divided into a control and a CDDP group (n = 6 for both), treated intraperitoneally with saline or CDDP 3 mg/kg, respectively. On day 0 and 5, we took serum samples and measured the SCre and BUN levels. The kidneys were obtained on day 5 and subjected to histological studies using HE staining. The serum samples were used for the comprehensive measurement of nine different trace metal types (Mn, Fe, Co, Ni, Cu, Zn, As, Se, and Mo) by ICP-MS. The statistical analysis was performed using Student's t-test.

Results

The SCre and BUN levels significantly increased in the CDDP group compared with those in the control group (P<0.01). The HE staining showed that the proximal tubular injury in the CDDP group was severe compared to that in the control group. Three out of nine serum trace metals, Co, Ni and Cu, were significantly high in the CDDP group compared with those in the control group (P<0.01).

Conclusion

Co, Ni, and Cu increased after the CDDP treatment. The measurement of such elements could be useful for the detection of CDDP-induced nephropathy.